Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
A look at the shareholders of Akebia Therapeutics, Inc. (NASDAQ:AKBA) can tell us which group is most powerful...
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced plans to r
Akebia Therapeutics Inc (NASDAQ:AKBA) was the target of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 6,780,000 shares, a decreas
Geode Capital Management LLC raised its position in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 5.0% in the fourth quarter, according to its most recent disclosure with the Securities and Excha

2 Small-Cap Stocks That Could Double Your Money

11:45am, Saturday, 18'th Apr 2020
Akebia Therapeutics and Satsuma Pharmaceuticals could both be big winners for early shareholders.
Nuveen Asset Management LLC grew its stake in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securit
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Renowned guru slims position in biotech company that focuses on kidney disease Continue reading...
Seth Klarman Dials Down Akebia Therapeutics Stake, Stocks: AKBA,TBPH,TBIO,ATRA,GOSS,PRTK, Seth Klarman, release date:Apr 14, 2020
Renaissance Technologies LLC increased its position in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 219.0% during the 4th quarter, according to its most recent disclosure with the Securities and
Raymond James & Associates lessened its holdings in shares of Akebia Therapeutics Inc (NASDAQ:AKBA) by 23.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 16,309
Jane Street Group LLC trimmed its stake in Akebia Therapeutics Inc (NASDAQ:AKBA) by 65.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission
In a report issued on April 9, Ed Arce from H.C. Wainwright maintained a Buy rating on Akebia Therapeutics (AKBA
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE